Published in final edited form as:

Nat Med. 2001 October ; 7(10): 1111–1117. doi:10.1038/nm1001-1111.

Ferredoxin reductase affects p53-dependent, 5-fluorouracil–induced apoptosis in colorectal cancer cells

Paul M. Hwang^{1,2,3}, Fred Bunz², Jian Yu², Carlo Rago¹, Timothy A. Chan², Michael P. Murphy⁴, Geoffrey F. Kelso⁵, Robin A. J. Smith⁵, Kenneth W. Kinzler², and Bert Vogelstein^{1,2}

¹Howard Hughes Medical Institute, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA ²Johns Hopkins Oncology Center, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA ³Cardiovascular Branch, NHLBI, NIH, Bethesda, Maryland, USA ⁴Wellcome Trust/MRC Building, Cambridge, UK ⁵Department of Chemistry, University of Otago, Dunedin, New Zealand

Abstract

Loss of p53 gene function, which occurs in most colon cancer cells, has been shown to abolish the apoptotic response to 5-fluorouracil (5-FU). To identify genes downstream of p53 that might mediate these effects, we assessed global patterns of gene expression following 5-FU treatment of isogenic cells differing only in their p53 status. The gene encoding mitochondrial ferredoxin reductase (protein, FR; gene, *FDXR*) was one of the few genes significantly induced by p53 after 5-FU treatment. The FR protein was localized to mitochondria and suppressed the growth of colon cancer cells when over-expressed. Targeted disruption of the *FDXR* gene in human colon cancer cells showed that it was essential for viability, and partial disruption of the gene resulted in decreased sensitivity to 5-FU-induced apoptosis. These data, coupled with the effects of pharmacologic inhibitors of reactive oxygen species, indicate that FR contributes to p53-mediated apoptosis through the generation of oxidative stress in mitochondria.

5-fluorouracil (5-FU) has been in clinical use for several decades and is still the most effective adjuvant therapy for patients with colon cancer. Metabolically, it acts by blocking the enzyme thymidylate synthase and by inhibiting both RNA and DNA synthesis. Like most chemotherapeutic agents, 5-FU induces marked apoptosis in sensitive cells. However, the molecular mechanisms underlying this apoptosis are only beginning to be elucidated.

Several studies have suggested a correlation between inactivation of p53 and resistance to 5-FU, both in patients and in experimental systems^{1,2}. For example, a profound resistance to 5-FU-induced apoptosis was observed in a human colon cancer cell line with a targeted disruption of the p53 gene (*Trp53*)³. Such observations support a genetic basis for 5-FU chemosensitivity and indicate that isogenic cells differing only in p53 status represent a useful system for studying chemosensitivity *in vitro*.

The mechanisms through which p53 induces apoptosis are the focus of much current research^{4–7}. Several studies have implicated mitochondria-derived reactive oxygen species (ROS) in the process^{8–11}. Though pro-apoptotic members of the Bcl-2 family of proteins have been shown to be induced by p53 and affect mitochondrial permeability, the molecular mechanisms responsible for the formation of mitochondrial ROS remain unclear^{12,13}.

In an effort to gain further insight into this process, we examined global patterns of gene expression using the serial analysis of gene expression (SAGE) approach¹⁴. We were particularly interested in finding p53-induced genes that encode mitochondrial proteins with the potential to directly stimulate ROS production. Here we identify mammalian ferredoxin reductase (FR) as a novel downstream mediator of p53 that fulfills this function.

Serial analysis of gene expression

The substantial difference in the 5-FU-sensitivity of isogenic HCT116 cell lines differing only in p53 status provided an ideal system for gene expression profiling³. SAGE libraries were constructed from mRNA of HCT116 *TRP53*^{+/+} and *TRP53*^{-/-} cell lines that had been treated with 5-FU for 18 hours, well before morphologic features of apoptosis were evident. A total of 50,370 and 51,088 SAGE tags were obtained from the cells with and without functional p53 genes, respectively. These tags corresponded to 8,421 unique transcripts, diagrammed according to fold of induction or repression in Fig. 1a. Internal controls were provided by the p53-inducible genes *P21* and *PIG3* with SAGE tag ratios of 67:3 and 13:0, respectively, in the libraries from the *TRP53*^{+/+} and *TRP53*^{-/-} cell lines.

Only 14 previously identified genes were found to be induced greater than five-fold in the *TRP53*^{+/+} cells. Among these were p21, PIG3 and tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor 2 (DR-5, KILLER) (Table 1). We identified 11 other significantly induced tags that did not correspond to any previously characterized genes and six genes that were repressed greater than five-fold; these were not pursued further.

Unexpectedly, one of the genes induced by p53 was *FDXR* (SAGE tag ratio 22:2). This gene had not previously been associated with p53 or with apoptosis. Northern blots confirmed that its induction by 5-FU was strictly dependent on functional p53 (Fig. 1b). *FDXR* mRNA began to be induced as early as three hours, indicating that it was a direct transcriptional target of p53. Accordingly, we found a perfect *TRP53* DNA-binding consensus sequence (GGGCTTGCCC)¹⁵ 33 bp upstream of the transcription start site. *FDXR* mRNA was induced in response to 5-FU in another colon cancer cell line with wild-type *TRP53* (SW48) but not in DLD1 cells with mutant *TRP53* (data not shown). Infection with adenoviruses expressing wild-type but not mutant *TRP53* also induced *FDXR* mRNA in other colon cancer cell lines, indicating that p53 itself, rather than some other effect of 5-FU, was responsible for this induction (Fig. 1c).

FR (also called adrenodoxin reductase) is the sole mammalian mitochondrial cytochrome P-450 NADPH reductase, and is located on the matrix side of the inner mitochondrial membrane^{16–18}. FR is responsible for transferring electrons from NADPH, via the single electron shuttle ferredoxin, to substrates such as cholesterol. Importantly, under substrate-limiting conditions, electrons can leak from this shuttling system and generate superoxide.

Thus, FR has been labeled an ‘electron gun’^{19,20}. These previously described biochemical properties, together with its induction by p53, stimulated us to determine whether this gene might have a previously unsuspected role in p53-dependent apoptosis.

Over-expression of FR inhibits cell growth

In order to study the effect of *FDXR* over-expression on cell growth, we cloned wild-type and deletion mutant *FDXR-GFP* (green fluorescent protein gene) fusion constructs into a tetracycline (tet)-inducible vector. The mutant construct retained only the mitochondrial-targeting domain located at the N-terminus and was missing the NADPH and FAD binding domains. Transient expression of these constructs in the DLD1 cell line resulted in robust expression of both the wild-type and mutant fusion proteins, as visualized by GFP fluorescence (Fig. 2a). This fluorescence colocalized with that from MitoTracker Red dye, indicating that both the wild-type and mutant fusion proteins were correctly targeted to the mitochondria (Fig. 2a).

We next attempted to establish stable transfectants that would express wild-type or mutant *FDXR-GFP* fusion proteins, using DLD-1 cells containing an inducible tet activator construct²¹. We obtained numerous clones for both wild-type and mutant fusion genes, however, only the mutant *FDXR-GFP* clones exhibited robust GFP expression upon induction. We were unable to obtain any clones expressing significant levels of the wild-type *FDXR-GFP* fusion protein by fluorescence or by western-blot analysis (data not shown). One stable wild-type clone with high levels of mitochondrial GFP fluorescence turned out to have a *de novo* truncation of the *FDXR-GFP* fusion protein upon western-blot analysis. These results indicated that FR had a potent growth-suppressive effect, so that even the low levels of FR expression afforded in the presence of doxycycline repression precluded clonal outgrowth. Fig. 2b summarizes the colony survival results after transfection of the wild-type *FDXR-GFP* and mutant *FDXR-GFP* fusion genes as well as a control mitochondrial gene superoxide dismutase (MnSOD). While the mutant *FDXR-GFP* construct, devoid of the oxidoreductase domain, yielded as many colonies as the control MnSOD gene, expression of the wild-type *FDXR-GFP* fusion gene largely eliminated colony outgrowth (Fig. 2b).

Disruption of *FDXR* by targeted homologous recombination

To more rigorously determine the role of FR in 5-FU apoptosis, we performed targeted disruptions of the *FDXR* gene in the HCT116 cell line. Two targeting constructs (KO-1 and KO-2) were designed, each containing the neomycin-resistance gene flanked by *loxP* sites but with homology arms of different lengths (Fig. 3a). Targeted homologous recombination was performed as described²². The frequency of targeted *FDXR* gene disruption in parental HCT116 cells was approximately 1:10,000 and 1:3,000 with the KO-1 and KO-2 constructs, respectively. After confirming homologous recombination by Southern-blot analysis, adenovirus-Cre-mediated excision of the neomycin-resistance gene allowed us to use the same KO-1 or KO-2 constructs to disrupt the second allele. The two-allele *FDXR* knockout frequency was approximately 1:5,000 using the KO-2 construct, consistent with predictions from the frequency of one-allele knockout clones.

Surprisingly, subclones that clearly had two alleles knocked out when assessed by PCR and Southern-blotting techniques still had one intact copy of the *FDXR* gene. Further analysis of this unexpected result revealed that the largely diploid HCT116 cell line had three copies of the *FDXR* gene. The *FDXR* gene is normally on chromosome 17q (ref. 17). In HCT116 there is a third copy located on an abnormal chromosome 18 that contains a small segment of chromosome 17q fused to the telomeric end of 18p (ref. 23). Fig. 3b shows the Southern blot of the wild-type (+/+), one-allele *FDXR* knockout (+/+⁻) and two-allele *FDXR* knockout (+/+^{-/-}) clones. We obtained four independent clones (D2, C2, E9 and B7) in which two *FDXR* alleles had been disrupted (*FDXR*^{+/-/-}). The genotypes of these clones were determined using two single nucleotide polymorphisms (SNPs; T1017C and C1046T) at the 3' end of intron 2. These SNPs defined two alleles of *FDXR*, termed A and B (Fig. 3c). The parental HCT116 contained one A allele and two B alleles, indicating that the B allele was the one translocated to chromosome 18p. Of the four *FDXR*^{+/-/-} heterozygotes, clone C2 retained allele B and lost one copy each of allele A and allele B, while clones D2, E9 and B7 retained allele A and had therefore lost both copies of allele B (Fig. 3c).

To disrupt the third *FDXR* allele, we transfected the two-allele knockout clones with the KO-2 construct. We found no *FDXR*^{-/-/-} clones among more than 80,000 clones screened. This represented eight-fold more clones than estimated to be necessary for disrupting the third allele. Because it was possible to independently disrupt each of the three alleles individually (Fig. 3c), our inability to disrupt all three alleles in combination strongly suggested that *FDXR* is essential for the viability of HCT116 cells.

***FDXR*^{+/-/-} clones show altered 5-FU induced apoptosis**

Compared to the fraction of apoptotic cells in the parental cell line and in two sister clones with three intact copies of *FDXR*, there was significantly less apoptosis in the *FDXR*-knockout clones at 12.5 and 25 μ M 5-FU ($7 \pm 1\%$ and $18 \pm 3\%$, respectively) versus wild-type cells ($14 \pm 2\%$ and $35 \pm 3\%$, respectively) (Fig. 4a). The resistance to 5-FU-induced apoptosis was not complete in these *FDXR*^{+/-/-} clones, as higher levels of 5-FU or longer periods of exposure to 5-FU induced apoptosis in all clones tested (data not shown). Another HCT116 derivative, in which *P21* had been disrupted by targeted homologous integration, showed similar sensitivity to 5-FU as the parental cells (Fig. 4a). Undiminished levels of 5-FU-induced apoptosis were also observed in HCT116 cells with the gene encoding 14-3-3 σ (*DIIRUBI3*) disrupted or with both *P21* and *DIIRUBI3* disrupted (data not shown). Thus the gene disruption procedure *per se* did not account for the decreased sensitivity of the *FDXR*^{+/-/-} clones to 5-FU, which was quite specific. We also performed western-blot analysis on both the HCT116 wild-type and *FDXR*^{+/-/-} cell lines for the induction of *TRP53* and *P21* proteins after 5-FU treatment (Web Supplement, Fig. A). Both proteins were significantly induced in all clones, indicating an intact 5-FU response as measured by these parameters.

Indicators of apoptosis in the knockout clones

A polyclonal antibody to FR protein was generated in rabbits following immunization with a FR synthetic peptide, and used to assess FR protein expression by western blotting. After 48

hours of treatment with 5-FU, FR protein expression was clearly induced in the parental cell line (wild-type, Fig. 4*b*). In comparison, the basal and 5-FU-induced levels of FR protein were decreased in all four *FDXR*^{+/-} clones (examples in Fig. 4*b*). No FR protein was induced in *TRP53*^{-/-} cells, consistent with the dependence of *FDXR* mRNA induction on p53 (Fig. 1*b*).

It has been shown that cleavages of caspase 9 and β -catenin are relatively early markers of apoptosis²⁴. The protein levels of both caspase 9 precursor and intact β -catenin were seen to decrease in parental HCT116 cells treated with 5-FU, concomitant with the appearance of smaller immunoreactive peptides. In contrast, the *FDXR*^{+/-} and *TRP53*^{-/-} clones showed negligible reductions in the full-length proteins after 5-FU treatment (Fig. 4*b*).

Flow cytometry and quantification of apoptosis

Treatment of wild-type parental cells (WT-Par) with 5-FU resulted in pronounced changes in cell cycle distributions. These included the elimination of the normal 4N peak, blunting of the 2N peak, and many sub-2N cells (Fig. 4*c* and *d*). We observed nearly identical patterns following treatment of two wild-type subclones (WT-A1 and WT-E1) with three intact *FDXR* alleles. In contrast, treatment of *TRP53*^{-/-} cells induced a G1 arrest (70% 2N fraction) and an absence of cells in G2 (4N), with no increase in apoptotic (sub-G1) cells.

The *FDXR*^{+/-} clones (D2, C2, E9 and B7) showed a markedly different cell-cycle response with higher retention of G2 cells (32% versus only 13% in parental cells). The absence of a G2 peak in the *TRP53*^{-/-} cells, but not in the *FDXR*^{+/-} cells, is consistent with the absence of a G2 checkpoint that is dependent on p53 but not upon FR (ref. 25). Moreover, there was a smaller proportion of apoptotic cells (sub-G1, 17 $\pm$ 4%) in the *FDXR*^{+/-} cells compared with those with three intact *FDXR* genes (30 $\pm$ 6%) (Fig. 4*c*). This 43% reduction in apoptotic cells was similar to that determined from morphological observations (49% reduction at 25 μ M 5-FU, Fig. 4*a*).

Relationship between oxidative stress and 5-FU treatment

To determine whether the disruption of *FDXR* alleles affected the generation of ROS, we assessed cells 24 hours following 5-FU treatment when no significant morphological evidence of apoptosis was apparent. The parental HCT116 (wild-type) cells demonstrated a significant amount of ROS, indicated by green staining with dichlorofluorescein (DCF) after digitonin permeabilization (Fig. 5*a*). In contrast, the *TRP53*^{-/-} cells and the two *FDXR*^{+/-} clones (D2 and C2) showed significantly less DCF staining. It has been shown that digitonin permeabilization of the plasma membrane facilitates mitochondrial localization of DCF in cells that are stressed with an apoptotic stimulus²⁶. The green DCF fluorescence in parental cells following 5-FU treatment colocalized with the mitochondrial MitoTracker Red staining (Fig. 5*b*).

To determine whether 5-FU induced apoptosis is dependent on ROS generation, we used a pharmacologic approach. Ubiquinol is a powerful antioxidant that has been evaluated extensively due to its role in mitochondrial function and metabolism. A recently developed derivative of ubiquinol, mitoQ, is specifically targeted to mitochondria through its covalent

attachment to the lipophilic cation triphenylmethyl phosphonium (TPMP)²⁷. Treatment with as little as 0.3 μ M mitoQ partially blocked 5-FU–induced apoptosis while 1 μ M completely blocked it (Fig. 5c). The carrier molecule TPMP alone or free ubiquinol had no effect (Fig. 5c). The less powerful antioxidant vitamin E had no effect alone, but when conjugated to TPMP it also effectively blocked 5-FU apoptosis at 10 μ M.

We examined two other human colorectal cancer cell lines (SW48 and RKO) with apparently intact p53 function to determine whether mitoQ could block 5-FU induced apoptosis. Only a minor effect was observed with SW48 cells (data not shown) but 1 μ M mitoQ completely blocked apoptosis in RKO cells (Fig. 5c).

To ensure that mitoQ does not exert toxic effects on cells, thereby nonspecifically inhibiting the apoptotic process, we performed colony formation assays after exposing HCT116 cells to 1 μ M mitoQ for 20 hours. Compared to control, there was no significant difference in the number of clones surviving after mitoQ treatment (Fig. 5d).

Clonogenicity assays provide a more stringent test of chemosensitivity than apoptosis assays. Cells with disrupted *TRP53*, for example, are resistant to 5-FU–induced apoptosis but still do not form colonies after 5-FU treatment³. To test whether mitoQ could prevent reduced clonogenicity after 5-FU treatment, we pretreated cells for 8 hours with 1 μ M mitoQ, then applied 50 μ g/ml 5-FU for an additional 12 hours. The mitoQ pretreatment had a dramatic effect on clonogenicity (Fig. 5d), further emphasizing the critical importance of mitochondrial ROS in the responses to 5-FU.

Discussion

The assessment of global gene-expression profiles in cells differing in only a single gene has great potential for elucidating the basis for pharmacologic action. Although the apoptosis following 5-FU treatment is completely dependent on the presence of intact p53 expression, our results demonstrate that only a small number of genes, including particularly *FDXR*, are induced by 5-FU in a p53-dependent manner.

Notably, we show here that a partial disruption of *FDXR* had a major effect on p53-induced apoptosis. We had expected such major effects only after complete disruption of the *FDXR* gene, as previous disruptions of p53-dependent genes have resulted in significant phenotypes only when all copies had been eliminated. In the case of *FDXR*, it was impossible to disrupt all three copies, as *FDXR* is apparently an essential gene. A requirement for FR is consistent with the fact that ferredoxin is essential for all cellular Fe-S enzyme biogenesis and with experiments in *Saccharomyces cerevisiae* demonstrating that the yeast *FDXR* homolog *ARH1* is an essential gene^{28–30}.

Colony formation assays on cells treated with mitoQ prior to 5-FU showed that the level of oxidative stress in mitochondria is critical for long-term colony survival (Fig. 5c). Notably, neither p53-deficiency nor partial knockout of *FDXR* allowed cells to survive 5-FU treatment when measured by clonogenic assays. Therefore, it appears that 5-FU toxicity involves more than p53, or any of its downstream mediators, including FR, and that p53 impacts only the short-term apoptotic response to 5-FU, not the longer-term growth

inhibition. However, the mitoQ rescue of clonogenicity dramatically emphasizes the importance of mitochondrial ROS in determining cellular fate after 5-FU treatment.

As more has been learned about p53, it has become apparent that there is a reaction to nearly every p53 action³¹. For example, MDM2 negatively regulates p53 protein stability, but p53 positively regulates MDM2 expression, creating a negative feedback loop. A similar cross-regulatory phenomenon appears to apply to p53 and ROS. It has recently been shown that inhibition of the NADH quinone oxidoreductase 1 (NQO1, PIG3) can inhibit p53 induction following exposure to irradiation and can thereby interfere with p53-dependent apoptosis³². Our studies show that mitoQ and mitoVitE, two new antioxidants specifically targeted to mitochondria, completely eliminated 5-FU-induced apoptosis, whereas their non-targeted derivatives were inactive. Interestingly, this abrogation of apoptosis was associated with markedly less p53 protein when assessed by western blots (data not shown). The disruption of two *FDXR* alleles also significantly attenuated apoptosis, though p53 protein was still induced by 5-FU. Together, these results suggest a feed-forward loop between the production of ROS, the stabilization of p53 protein and the consequent induction of apoptosis. Though the physiologic stimulant of p53 stabilization remains to be defined³³, we hypothesize that one important stimulant involves ROS and that a primary evolutionary function of p53 will be to protect cells from the effects of oxidative stress. At the animal level, this idea can be tested in mice, *Drosophila* and *Caenorhabditis elegans* with disruptions of their ferredoxin reductase homologs.

Methods

Cell culture and reagents

The human colon cancer cell lines HCT116, DLD1, SW48, SW480 and RKO (American Type Culture Collection, Manassas, Virginia) were maintained in McCoy's 5A modified medium (Life Technologies, Grand Island, New York) supplemented with 10% FBS and penicillin/streptomycin (Gibco-BRL). The RPE cell line 911 was provided by A. J. Van der Eb. The derivations of the various cell lines and p53 adenovirus used in this study have been published^{3,21,34}. Cells were treated with 5-fluorouracil at 50 µg/ml unless otherwise indicated.

Serial analysis of gene expression

The HCT116 *TRP53*^{+/+} and *TRP53*^{-/-} cell lines were treated with 5-FU for 18 h prior to mRNA purification. A modified version of SAGE was performed as described (Micro-SAGE; www.sagenet.org/sage_protocol.htm). Differentially expressed tags were considered significant if the fold induction was ≥ 5 and the probability of induction was *P-False* < 0.05 by Monte Carlo analysis³⁵.

Northern-blot analysis

Total RNA was purified using RNAgents kit (Promega, Madison, Wisconsin); 10-µg samples of RNA were separated in 1.5% agarose-formaldehyde gels. RNA was transferred onto Zeta-Probe GT Genomic blotting membrane (Bio-Rad, Hercules, California) and

hybridized in QuickHyb (Stratagene, La Jolla, California)³⁵. Probes for northern blotting were generated by PCR using cDNA or ESTs as template and labeled by random priming³⁶.

MnSOD and *FDXR* fusion constructs and transfections

The MnSOD and *FDXR* constructs were made by PCR amplification from full-length ESTs and their coding sequences confirmed. The *FDXR-GFP* fusion gene was derived from pEGFP-N1 then subcloned into pTRE (Clontech, Palo Alto, California). The mutant *FDXR* construct was made by deleting amino acids 43–497 and by joining the mitochondrial leader sequence to the N-terminus of *GFP*. MnSOD was cloned into the pBi-MCS-GFP vector and the expression of MnSOD protein confirmed by western-blot analysis (data not shown)²¹. Transient and stable transfections were carried out in 911-tet and DLD1-tet cells ((tet)-off inducible system) as described²¹. The construct gene and pTK-hyg (Clontech) were stably cotransfected at a 5:1 molar ratio and clones selected with Hygromycin-B at 250 µg/ml (Calbiochem, La Jolla, California).

Mitochondrial colocalization studies

Confocal microscopy was used to visualize GFP expression 24 h after transient transfection of 911-tet cells. For colocalization studies, cells were incubated with 0.5 µM MitoTracker Red (Molecular Probes, Eugene, Oregon) at 37 °C for 30 min.

Targeted disruption of *FDXR* by homologous recombination

The KO-1 and KO-2 targeting constructs were made by PCR amplifying the *FDXR* gene from HCT116 genomic DNA. The KO-2 construct represented a bipartite targeting vector system with an additional recombination site designed into the middle portion of the neomycin resistance gene³⁷. Transfection, selection and PCR screening strategies for somatic-cell homologous recombination have been described²². Because the frequency of recombination at the *FDXR* gene locus was relatively low, recombinant clones were screened in pools. Correctly targeted recombinant clones were cloned by limiting dilution and their genomic DNA analyzed by Southern blotting. The neomycin-resistance gene was excised by infection with an adenovirus expressing Cre recombinase prior to another round of homologous recombination³⁸.

Apoptosis assays

For 5-FU sensitivity the loose cells in the media were pooled with the trypsinized cells and stained with Hoechst 33258 dye³⁹. Apoptosis was scored by fluorescence microscopy and analyzed by flow cytometry.

FR antibody production and western-blot analysis

A FR synthetic peptide (aa473–490) was used to immunize rabbits and the sera were affinity purified (Quality Controlled Biochemicals, Hopkinton, Massachusetts). Western blotting of total protein lysates was performed as described²². The purified antibody against FR reacted with a single band of 52 kD corresponding to processed FR. A rabbit polyclonal antibody against caspase-9 (SC-7890, Santa Cruz Biotechnology, Santa Cruz, California) and a

mouse monoclonal antibody against β -catenin (C19220, Transduction Laboratories) were also used.

DCF staining in plasma membrane-permeabilized cells

Cells were treated with 5-FU for 24 h and then incubated with 1 μ M DCF (carboxy-dichlorofluorescein diacetate, Molecular Probes, Eugene, Oregon) in 50 μ g/ml digitonin at 37 °C for 15 min²⁶. These cells were then examined by phase, confocal and fluorescence microscopy.

Colony formation assay

HCT116 wild-type cells were treated with 1 μ M mitoQ for 20 h prior to plating in T-25 flasks. For the post-5-FU exposure colony formation assay, the mitoQ pretreated cells were incubated with 1 μ M mitoQ for 8 h, prior to the addition of 50 μ g/ml 5-FU for an additional 12 h. The indicated number of cells were then plated in drug-free medium in T-25 flasks and stained with crystal violet after 7–14 d.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

We thank L. Meszler for help with cell imaging and all members of the Kinzler/Vogelstein Laboratories for advice and discussion. This work was supported by the Clayton Fund, the Miracle Foundation, and NIH grants CA 43460 and GM 07184. K.W.K. receives research funding from Genzyme Molecular Oncology (Genzyme) and K.W.K. and B.V. are consultants to Genzyme. Under a licensing agreement between the Johns Hopkins University and Genzyme, the SAGE technology was licensed to Genzyme, and K.W.K. and B.V. are entitled to a share of royalty received by the University from sales of the licensed technology. The terms of these arrangements are being managed by the University in accordance with its conflict of interest policies.

References

1. O'Connor PM, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. *Cancer Res.* 1997; 57:4285–300. [PubMed: 9331090]
2. Lowe SW, et al. p53 status and the efficacy of cancer therapy *in vivo*. *Science.* 1994; 266:807–810. [PubMed: 7973635]
3. Bunz F, et al. Disruption of p53 in human cancer cells alters the responses to therapeutic agents. *J Clin Invest.* 1999; 104:263–269. [PubMed: 10430607]
4. Oren M. Regulation of the p53 tumor suppressor protein. *J Biol Chem.* 1999; 274:36031–36034. [PubMed: 10593882]
5. Prives C, Hall PA. The p53 pathway. *J Pathol.* 1999; 187:112–126. [PubMed: 10341712]
6. El-Deiry WS. Regulation of p53 downstream genes. *Semin Cancer Biol.* 1998; 8:345–357. [PubMed: 10101800]
7. Giaccia AJ, Kastan MB. The complexity of p53 modulation: emerging patterns from divergent signals. *Genes Dev.* 1998; 12:2973–2983. [PubMed: 9765199]
8. Johnson TM, Yu ZX, Ferrans VJ, Lowenstein RA, Finkel T. Reactive oxygen species are downstream mediators of p53-dependent apoptosis. *Proc Natl Acad Sci USA.* 1996; 93:11848–11852. [PubMed: 8876226]
9. Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B. A model for p53 induced apoptosis. *Nature.* 1997; 389:300–304. [PubMed: 9305847]

10. Lee JM. Inhibition of p53-dependent apoptosis by the KIT tyrosine kinase: regulation of mitochondrial permeability transition and reactive oxygen species generation. *Oncogene*. 1998; 17:1653–1662. [PubMed: 9796694]
11. Li PF, Dietz R, von Harsdorf R. p53 regulates mitochondrial membrane potential through reactive oxygen species and induces cytochrome c-independent apoptosis blocked by Bcl-2. *EMBO J*. 1999; 18:6027–6036. [PubMed: 10545114]
12. Green DR, Reed JC. Mitochondria and apoptosis. *Science*. 1998; 281:1309–12. [PubMed: 9721092]
13. Kroemer G, Reed JC. Mitochondrial control of cell death. *Nature Med*. 2000; 6:513–519. [PubMed: 10802706]
14. Velculescu VE, Zhang L, Vogelstein B, Kinzler KW. Serial Analysis Of Gene Expression. *Science*. 1995; 270:484–487. [PubMed: 7570003]
15. El-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. *Nature Genet*. 1992; 1:45–49. [PubMed: 1301998]
16. Lambeth JD, Seybert DW, Lancaster JR, Salerno JC, Kamin H. Steroidogenic electron transport in adrenal cortex mitochondria. *Mol Cell Biochem*. 1982; 45:13–31. [PubMed: 7050653]
17. Lin D, Shi YF, Miller WL. Cloning and sequence of the human adrenodoxin reductase gene. *Proc Natl Acad Sci USA*. 1990; 87:8516–8520. [PubMed: 2236061]
18. Ziegler GA, Vornrhein C, Hanukoglu I, Schulz GE. The structure of adrenodoxin reductase of mitochondrial P450 systems: electron transfer for steroid biosynthesis. *J Mol Biol*. 1999; 289:981–990. [PubMed: 10369776]
19. Rapoport R, Sklan D, Hanukoglu I. Electron leakage from the adrenal cortex mitochondrial P450_{scc} and P450_{c11} systems: NADPH and steroid dependence. *Arch Biochem Biophys*. 1995; 317:412–416. [PubMed: 7893157]
20. Hanukoglu I, Rapoport R, Weiner L, Sklan D. Electron leakage from the mitochondrial NADPH-adrenodoxin reductase- adrenodoxin-P450_{scc} (cholesterol side chain cleavage) system. *Arch Biochem Biophys*. 1993; 305:489–498. [PubMed: 8396893]
21. Yu J, et al. Identification and classification of p53-regulated genes. *Proc Natl Acad Sci USA*. 1999; 96:14517–14522. [PubMed: 10588737]
22. Chan TA, Hermeking H, Lengauer C, Kinzler KW, Vogelstein B. 14-3-3Sigma is required to prevent mitotic catastrophe after DNA damage. *Nature*. 1999; 401:616–620. [PubMed: 10524633]
23. Masramon L, et al. Cytogenetic characterization of two colon cell lines by using conventional G-banding, comparative genomic hybridization, and whole chromosome painting. *Cancer Genet Cytogenet*. 2000; 121:17–21. [PubMed: 10958935]
24. Yu J, Zhang L, Hwang PM, Kinzler KW, Vogelstein B. PUMA induces the rapid apoptosis of colorectal cancer cells. *Molecular Cell*. 2001; 7:673–682. [PubMed: 11463391]
25. Bunz F, et al. Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science*. 1998; 282:1497–1501. [PubMed: 9822382]
26. Pham NA, Robinson BH, Hedley DW. Simultaneous detection of mitochondrial respiratory chain activity and reactive oxygen in digitonin-permeabilized cells using flow cytometry. *Cytometry*. 2000; 41:245–251. [PubMed: 11084609]
27. Kelso GF, et al. Selective targeting of a redox-active ubiquinone to mitochondria within cells: Antioxidant and antiapoptotic properties. *J Biol Chem*. 2001; 276:4588–4596. [PubMed: 11092892]
28. Lill R, Kispal G. Maturation of cellular Fe-S proteins: an essential function of mitochondria. *Trends Biochem Sci*. 2000; 25:352–356. [PubMed: 10916152]
29. Manzella L, Barros MH, Nobrega FG. ARH1 of *Saccharomyces cerevisiae*: A new essential gene that codes for a protein homologous to the human adrenodoxin reductase. *Yeast*. 1998; 14:839–846. [PubMed: 9818721]
30. Li J, Saxena S, Pain D, Dancis A. Adrenodoxin reductase homolog (Arh1p) of yeast mitochondria required for iron homeostasis. *J Biol Chem*. 2001; 276:1503–1509. [PubMed: 11035018]
31. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. *Nature*. 2000; 408:307–310. [PubMed: 11099028]

32. Asher G, Lotem J, Cohen B, Sachs L, Shaul Y. Regulation of p53 stability and p53-dependent apoptosis by NADH quinone oxidoreductase 1. *Proc Natl Acad Sci USA*. 2001; 98:1188–1193. [PubMed: 11158615]
33. Meek DW. Mechanisms of switching on p53: a role for covalent modification? *Oncogene*. 1999; 18:7666–7675. [PubMed: 10618706]
34. Waldman T, Kinzler KW, Vogelstein B. p21 is necessary for the p53-mediated G(1) arrest in human cancer cells. *Cancer Res*. 1995; 55:5187–5190. [PubMed: 7585571]
35. Zhang L, et al. Gene expression profiles in normal and cancer cells. *Science*. 1997; 276:1268–1272. [PubMed: 9157888]
36. Feinberg AP, Vogelstein B. A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity. *Anal Biochem*. 1983; 132:6–13. [PubMed: 6312838]
37. Jallepalli PV, et al. Securin is required for chromosomal stability in human cells. *Cell*. 2001; 105:445–457. [PubMed: 11371342]
38. He TC, et al. A simplified system for generating recombinant adenoviruses. *Proc Natl Acad Sci USA*. 1998; 95:2509–2514. [PubMed: 9482916]
39. Waldman T, Lengauer C, Kinzler KW, Vogelstein B. Uncoupling of S phase and mitosis induced by anticancer agents in cells lacking p21. *Nature*. 1996; 381:713–716. [PubMed: 8649519]

Fig. 1.

Summary of SAGE data and northern-blot analysis of *FDXR* mRNA induction. **a**, Graphic representation of the number of unique transcripts stratified according to the fold that they were induced or repressed. *P-False* > 0.05 (ref. 35). **b**, Time course of *FDXR* mRNA (1.8 kb) induced by 5-FU at the indicated time in HCT116 cells with wild-type (WT) or *TRP53*^{-/-}. **c**, *FDXR* mRNA induction 18 h after infection with an adenovirus expressing mutant (M) or wild-type (W) p53 in the indicated colon cancer cell lines. SW480 and DLD1 have mutated *TRP53* whereas HCT116 and SW48 have wild-type. The film exposure for the

TRP53^{-/-} cells was longer, enabling detection of the lower basal levels of *FDXR* mRNA in these lines. The lower basal level is consistent with the transcriptional dependence of FR expression on p53. GAPDH served as controls for relative amounts of RNA in all lanes.

Fig. 2.

Expression of *FDXR*-GFP fusion proteins. **a**, 911 cells were transfected with wild-type (WT) or deletion mutant (MUT) *FDXR*-GFP construct and its expression assessed with fluorescence microscopy. MitoTracker Red specifically labels the mitochondria and colocalizes with the *FDXR*-GFP (green). **b**, The fraction of stable clones that expressed GFP after doxycycline withdrawal in clones transfected with the indicated genes and grown in selective media for 14 d.

Fig. 3. *FDXR* targeting constructs. **a**, Structure of the targeting constructs aligned with the *FDXR* gene, containing 12 exons (numbered vertical bars). **b**, Southern blot of parental HCT116 (+/+), one-allele *FDXR* knockout (+/+/-) and two-allele *FDXR* knockout (+/-/-) cells. The WT and the knockout bands are indicated, before (+neo) and after (-neo) Cre-recombinase excision of the neomycin gene from the *FDXR* heterozygotes. The *FDXR* knockout clones depicted here were obtained using the KO-1 construct. **c**, SNP determination of parental HCT116 (lane 1), *FDXR*^{+/+/-} (lane 2), and four different *FDXR*^{+/+/-} clones (lanes 3, 4, 5 and 6). Note that the relative intensities of the SNP:non-SNP sequence bands show 1:3, 1:2, and 1:1 intensity relationships corresponding to their respective *FDXR* genotypes.

Fig. 4.

FDXR^{+/-} clones are less sensitive to the apoptotic effects of 5-FU. **a**, The average percentage of apoptotic cells on the y-axis (mean $\pm$ s.e. of the mean) after 48 h of treatment at the indicated dose of 5-FU (x-axis) is shown for HCT116 WT (■, average of parental cells plus 2 independent wild-type sister subclones), HCT116 *FDXR*^{+/-} (■, average of clones D2, C2, E9 and B7), and HCT116 *TRP53*^{-/-} (■) and p21^{-/-} clones (□). At least 100–300 cells were counted in duplicate for each data point and each experiment was repeated at least 3 times. **b**, Western blots using antibodies against FR, caspase 9 and β -catenin to sequentially probe the same membrane after stripping. Cells were treated with (+) or without (–) 5-FU for 48 h. **c**, Percentage of cells with DNA contents corresponding to ■, SubG1; ■, G1, □, S; and ■, G2, as determined by flow cytometry. Percentages and error bars ($n=3$) from one representative experiment, repeated at least three times with similar results. **d**, Flow cytometry profiles of the parental wild-type HCT116 (WT-Par), 2 wild-type

sister sub-clones (WT-A1 and WT-E1), a *TRP53*^{-/-} clone and 4 *FDXR*^{+/-/-} clones (D2, C2, E9 and B7) before (0 h) and after (48 h) treatment with 5-FU. Cells with 2N DNA content correspond to those in G1 while cells in the 4N peak are in G2/M. These experiments were repeated at least three times with similar results.

Fig. 5.

Increased DCF signal is associated with 5-FU-induced apoptosis. **a**, Cells were stained with the ROS-indicator DCF 18 to 24 h after 5-FU treatment of parental wild-type HCT116 cells, a *TRP53*^{-/-} clone and two representative *FDXR*^{+/-/-} (D2 and C2) clones. All 5 photomicrographs were taken at equal magnification (×20) and exposure times. The corresponding phase contrast images are shown to demonstrate equivalent cell densities. **b**, The DCF staining in the WT digitonin-permeabilized cells is consistent with mitochondrial localization, as confirmed by colocalization with MitoTracker Red. **c**, Mean percentage of apoptotic cells (y-axis) in the parental HCT116 or RKO cells treated for 48 h with the indicated agents. For the noted conditions, cells were pretreated with TPMP, vitamin E (VitE), TPMP-vitamin E (MitoVitE), ubiquinol (Quinol) or TPMP-ubiquinol (MitoQ) for 18 h prior to 5-FU addition. **d**, Colony-formation assays for the noted treatment conditions before plating at the indicated cell densities in T-25 flasks.

Table 1

Genes induced or repressed following 5-FU treatment

Induced genes	SAGE Tag + (15th bp)	WT	KO	Ratio
Placental BMP homolog, TGF β superfamily	GTGCTCATTCa	24	0	>24
p21	TGTCCTGGTTc	67	3	22
Ribosomal protein	GCGGCAGCGGa	17	1	17
Acyl CoA thioester hydrolase	GCAACGGGCCc	15	0	>15
Ribosomal protein L28	GCGGCGGCTCc	30	2	15
PIG3 (quinone oxidoreductase homolog)	GAGGCCAACA	13	0	>13
Ferredoxin reductase/Adrenodoxin reductase	CTGGAAATAAa	22	2	11
DNA polymerase delta cat. subunit	GGGCGGGGGCg	32	3	11
TNF Related Apop Induc Lig Receptor 2	ACCAAATTAAa	19	2	10
PolyA binding protein	GGGTAGCTGGg	17	2	9
MHC class II antigen	CTCCACAAATt	24	3	8
Huntingtin interacting protein (364bp DNA)	GGCAACGTGGt	20	3	7
Ribosomal protein	GGCCCGAGTTa	23	4	6
TNF Recep 2 related prot (CD18)	CAAATAAAAAg	16	3	5
Induced ESTs	SAGE Tag + (15th bp)	WT	KO	Ratio
UI-1-similar to CGI-67 protein	TGGACCCCCCg	13	0	>13
UI-2-unknown	GGGGCAAAAAa	12	0	>12
UI-3-weakly similar to yeast TPR	TGGGTGGGGGg	18	1	18
UI-4-MKP-1-like prot tyr phosphatase, dual specificity	TGCCCAGGATt	16	1	16
UI-5-homeobox gene	GGCTGGGTTTt	15	1	15
UI-6-similar to protein transport protein sec61 beta	AGAGAAATTTc	14	1	14
UI-7-SH3 domain-containing protein	AGGGGCGCAGa	13	1	13
UI-8-EST	GGGAGGAGGGg	13	1	13
UI-9-yeast SCO1&2 homolog	GCGGCTTTCCg	17	2	9
UI-10-EST	TGGCGTGGCCg	28	3	9
UI-11-EST	GGTGCAGAGCc	38	5	8
Repressed genes	SAGE Tag + (15th bp)	WT	KO	Ratio
Protein tyrosine phosphatase, hPTPCAAX1	CATTATCATCt	0	20	0.025
Immunophilin homolog ARA9/Aryl hydrocarbon recep.	CTTCTGTGTAt	0	11	0.045
Survival motor neuron gene	GCTGTTCATTg	1	13	0.077
Repressed ESTs	SAGE Tag + (15th bp)	WT	KO	Ratio
UR-1-EST	TTGACACTTTc	0	21	0.024
UR-2-Unknown	TACTAGTCCCc	0	13	0.038
UR-3-EST	TAGTTGTAGGg	0	12	0.042

The candidate genes are listed in decreasing order of fold induction or fold repression ($P\text{-False} < 0.05$). The SAGE tag sequence and the identity of the 15th base (lower case letter) are shown. UI, unknown induced gene; UR, unknown repressed gene. All genes are designated by their product. (A complete list of the tags induced and repressed in this system is available as supplemental information at <http://www.sagenet.org>)